CompletedPhase 2Phase 3ACTRN12609000417280

Analysis of the immunomodulatory effects of Echinacea

investigations into the effects of supplementation with echinacea on parameters of the immune response in healthy adults

Sponsor

MediHerb Pty Ltd

Enrollment

20 participants

Start Date

May 20, 2009

Study Type

Interventional

Conditions

Immune system response

Summary

It is widely accepted that stimulation of the immune system is responsible for the perceived benefits of Echinacea. This study will examine the prophylactic use of echinacea on white cell counts, natural killer cell functionality, heat shock protein expression and echinacea pharmacokinetics.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study examines how Echinacea, a popular herbal supplement, affects the immune system in healthy adults aged 18 to 65. Researchers want to understand whether Echinacea can boost or change immune function. Participants must be free of respiratory illness for at least 2 weeks before the study begins.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The tablets contain 675mg herb equivalent of Echinacea purpurea and 600mg herb equivalent of Echinacea angustifolia. Participants will take 2 tablets twice a day for 2 weeks

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000417280